Investor Presentation • Jan 22, 2020
Investor Presentation
Open in ViewerOpens in native device viewer


(compared with the corresponding period a year ago)
| SEKm | 1912 | 1812 | % | 2019:4 | 2018:4 | % |
|---|---|---|---|---|---|---|
| Net sales | 128,975 | 118,500 | 9 | 33,686 | 31,112 | 8 |
| Adjusted operating profit before amortization of acquisition related intangible assets (EBITA)1 |
15,840 | 12,935 | 22 | 4,742 | 3,451 | 37 |
| Operating profit before amortization of acquisition-related intangible assets (EBITA) |
15,127 | 11,560 | 31 | 4,740 | 3,475 | 36 |
| Amortization of acquisition-related intangible assets | -778 | -732 | -202 | -195 | ||
| Adjusted operating profit1 | 15,062 | 12,203 | 23 | 4,540 | 3,256 | 39 |
| Items affecting comparability | -713 | -1,444 | -2 | -40 | ||
| Operating profit | 14,349 | 10,759 | 33 | 4,538 | 3,216 | 41 |
| Financial items | -1,309 | -1,157 | -303 | -236 | ||
| Profit before tax | 13,040 | 9,602 | 36 | 4,235 | 2,980 | 42 |
| Adjusted Profit before tax1 | 13,753 | 11,046 | 25 | 4,237 | 3,020 | 40 |
| Tax2 | -2,828 | -1,050 | -1,189 | 637 | ||
| Profit for the period2 | 10,212 | 8,552 | 192 | 3,046 | 3,617 | -162 |
| Earnings per share, SEK | 13.12 | 11.23 | 3.87 | 4.85 | ||
| Adjusted earnings per share, SEK3 | 14.69 | 13.32 | 4.10 | 4.97 |
1Excluding items affecting comparability. For amounts, see page 11. 2Full-year 2018 and the fourth quarter of 2018 were positively affected by a decision in a tax case in Sweden that reduced the tax cost by approximately SEK 1.1bn.
3Excluding items affecting comparability and amortization of acquisition related intangible assets.

Both growth and profitability increased for Essity in 2019. The Group's organic net sales rose 4.5%. Adjusted EBITA increased 22% while the adjusted EBITA margin rose 1.4 percentage points to 12.3%. Earnings were positively impacted by implemented price increases, a better product mix, higher volumes, cost savings and lower raw material costs. Stock revaluations due to lower raw material prices and higher distribution costs had a negative impact on earnings. Investments to increase growth resulted in higher sales and marketing costs. The adjusted return on capital employed rose by 1.8 percentage points to 13.8%. Earnings per share increased 17% to SEK 13.12. The Board of Directors proposes an increase in the dividend of 9% to SEK 6.25 per share.
During the year, we increased growth, improved profitability and strengthened our competitiveness for the future through:
The Group's net sales increased 8.3% in the fourth quarter of 2019 compared with the corresponding period a year ago. Organic net sales increased 3.6%, of which volume accounted for 2.3% and price/mix for 1.3%. In emerging markets, which accounted for 37% of net sales, organic net sales increased 6.6%, while the increase in mature markets was 1.9%.
The Group's adjusted EBITA in the fourth quarter of 2019 increased 37% compared with the corresponding period a year ago. Earnings were positively impacted by higher prices, a better product mix, higher volumes, lower raw material and energy costs and cost savings amounting to SEK 206m, of which SEK 202m were related to the cost-savings program. Investments to increase growth and higher costs for incentive programs resulted in increased sales and marketing costs. Higher distribution costs and stock revaluations due to lower raw material prices had a negative impact on earnings. Lower pulp prices have resulted in price pressure in the market for consumer tissue. In the Consumer Tissue business area, we have finalized some negotiations and agreed on price decreases in Europe. The agreed price decreases are on average low single-digits and will have an impact in the first quarter of 2020. The Group's adjusted EBITA margin increased 3.0 percentage points to 14.1%. The adjusted return on capital employed rose 3.7 percentage points to 16.4%. Operating cash flow increased 46%. Earnings per share were SEK 3.87.

Excluding items affecting comparability; for amounts see page 11.

| SEKm | 1912 | 1812 | % | 2019:4 | 2018:4 | % |
|---|---|---|---|---|---|---|
| Net sales | 128,975 | 118,500 | 9 | 33,686 | 31,112 | 8 |
| Cost of goods sold1 | -90,876 | -85,058 | -22,997 | -22,574 | ||
| Adjusted gross profit1 | 38,099 | 33,442 | 14 | 10,689 | 8,538 | 25 |
| Sales, general and administration1 | -22,259 | -20,507 | -5,947 | -5,087 | ||
| Adjusted operating profit before amortization of acquisition-related intangible 1 assets (EBITA) |
15,840 | 12,935 | 22 | 4,742 | 3,451 | 37 |
| Amortization of acquisition-related intangible assets1 | -778 | -732 | -202 | -195 | ||
| Adjusted operating profit1 | 15,062 | 12,203 | 23 | 4,540 | 3,256 | 39 |
| Financial items | -1,309 | -1,157 | -303 | -236 | ||
| Adjusted profit before tax1 | 13,753 | 11,046 | 25 | 4,237 | 3,020 | 40 |
| Adjusted tax1 | -2,987 | -1,490 | -1,178 | 602 | ||
| Adjusted profit for the period1 1Excluding items affecting comparability; for amounts see page 11. |
10,766 | 9,556 | 13 | 3,059 | 3,622 | -16 |
| Adjusted Margins (%) | ||||||
| Gross margin1 | 29.5 | 28.2 | 31.7 | 27.4 | ||
| EBITA margin1 | 12.3 | 10.9 | 14.1 | 11.1 | ||
| Operating margin1 | 11.7 | 10.3 | 13.5 | 10.5 | ||
| Financial net margin | -1.0 | -1.0 | -0.9 | -0.8 | ||
| Profit margin1 | 10.7 | 9.3 | 12.6 | 9.7 | ||
| Tax1 | -2.3 | -1.3 | -3.5 | 1.9 | ||
| Net margin1 | 8.4 | 8.0 | 9.1 | 11.6 |
1Excluding items affecting comparability; for amounts see page 11.
| SEKm | 1912 | 1812 | % | 2019:4 | 2018:4 | % |
|---|---|---|---|---|---|---|
| Personal Care | 6,746 | 6,354 | 6 | 1,756 | 1,652 | 6 |
| Consumer Tissue | 5,321 | 3,331 | 60 | 1,767 | 840 | 110 |
| Professional Hygiene | 4,463 | 3,841 | 16 | 1,408 | 1,085 | 30 |
| Other | -690 | -591 | -189 | -126 | ||
| Total1 | 15,840 | 12,935 | 22 | 4,742 | 3,451 | 37 |
1Excluding items affecting comparability; for amounts see page 11.
| SEKm | 1912 | 1812 | % | 2019:4 | 2018:4 | % |
|---|---|---|---|---|---|---|
| Personal Care | 6,014 | 5,663 | 6 | 1,567 | 1,470 | 7 |
| Consumer Tissue | 5,314 | 3,326 | 60 | 1,765 | 836 | 111 |
| Professional Hygiene | 4,424 | 3,805 | 16 | 1,398 | 1,076 | 30 |
| Other | -690 | -591 | -190 | -126 | ||
| Total1 1Excluding items affecting comparability; for amounts see page 11. |
15,062 | 12,203 | 23 | 4,540 | 3,256 | 39 |
| SEKm | 1912 | 1812 | % | 2019:4 | 2018:4 | % |
|---|---|---|---|---|---|---|
| Personal Care | 6,495 | 5,006 | 30 | 1,643 | 1,244 | 32 |
| Consumer Tissue | 4,870 | 2,388 | 104 | 1,857 | 1,503 | 24 |
| Professional Hygiene | 4,938 | 3,363 | 47 | 1,623 | 891 | 82 |
| Other | -664 | -857 | -370 | -393 | ||
| Total | 15,639 | 9,900 | 58 | 4,753 | 3,245 | 46 |



| Change in net sales (%) | ||||||
|---|---|---|---|---|---|---|
| 1912 vs 1812 |
19:4 vs 18:4 |
|||||
| Total | 8.8 | 8.3 | ||||
| Price/mix | 2.2 | 1.3 | ||||
| Volume | 2.3 | 2.3 | ||||
| Currency | 4.4 | 5.0 | ||||
| Acquisitions | 0.1 | 0.0 | ||||
| Divestments | -0.2 | -0.3 |
| 1912 vs 1812 |
19:4 vs 18:4 |
|
|---|---|---|
| Total | 22 | 37 |
| Price/mix | 19 | 9 |
| Volume | 8 | 6 |
| Raw materials | 6 | 43 |
| Energy | 0 | 3 |
| Currency | 6 | 8 |
| Other | -17 | -32 |
Excluding items affecting comparability


Net sales increased 8.8% compared with the corresponding period a year ago to SEK 128,975m (118,500). Organic net sales, which exclude exchange rate effects, acquisitions and divestments, increased 4.5%, of which volume accounted for 2.3% and price/mix for 2.2%. Organic net sales increased 2.1% in mature markets and increased 9.1% in emerging markets. Emerging markets accounted for 37% of net sales. Exchange rate effects increased net sales by 4.4%. Acquisitions in Latin America increased net sales by 0.1%. The divestment of the partly owned company SCA Yildiz in Turkey reduced net sales by 0.2%.
Adjusted operating profit before amortization of acquisition-related intangible assets (adjusted EBITA) increased 22% (16% excluding currency translation effects, acquisitions and divestments) to SEK 15,840m (12,935). Higher prices, a better product mix, higher volumes, cost savings and lower raw material costs had a positive impact on earnings. Cost savings amounted to SEK 1,093m, of which SEK 637m was related to the Group-wide cost-savings program. Stock revaluations, due to lower raw material prices, and higher distribution costs had a negative impact on earnings. Investments to increase growth resulted in higher sales and marketing costs.
Items affecting comparability amounted to SEK -713m (-1,444) and include costs of SEK -409m related to restructuring costs for the Group-wide cost-savings program. The divestment of the 50% stake in the partly owned company SCA Yildiz in Turkey resulted in a currency-related loss of SEK -149m that did not affect cash flow or shareholders' equity. Other costs negatively impacted items affecting comparability by SEK -155m.
Financial items increased to SEK -1,309m (-1,157). The increase is primarily related to higher interest and higher average net debt, mainly due to the new accounting standard for leases.
Adjusted profit before tax increased 25% (19% excluding currency translation effects, acquisitions and divestments) and amounted to SEK 13,753m (11,046).
The tax expense, excluding effects of items affecting comparability, was SEK 2,987m (1,490).
Adjusted profit for the period increased 13% (7% excluding currency translation effects, acquisitions and divestments) and amounted to SEK 10,766m (9,556).
Profit for the period increased 19% (13% excluding currency translation effects, acquisitions and divestments) to SEK 10,212m (8,552). Earnings per share were SEK 13.12 (11.23). The adjusted earnings per share were SEK 14.69 (13.32). Profit for the period in 2018 was positively affected by a decision in a tax case in Sweden that reduced the tax cost by approximately SEK 1.1bn.
The adjusted return on capital employed was 13.8% (12.0). The adjusted return on equity was 18.4% (18.0).
Net sales increased 8.3% compared with the corresponding period a year ago to SEK 33,686m (31,112). Organic net sales, which exclude exchange rate effects, acquisitions and divestments, increased 3.6%, of which volume accounted for 2.3% and price/mix for 1.3%. Organic net sales were positively impacted by a better price/mix and higher volumes in all business areas. Organic net sales increased 1.9% in mature markets and increased 6.6% in emerging markets. Emerging markets accounted for 37% of net sales. Exchange rate effects increased net sales by 5.0%. The divestment of the jointly owned company SCA Yildiz in Turkey reduced net sales by 0.3%.
Adjusted operating profit before amortization of acquisition-related intangible assets (adjusted EBITA) increased 37% (29% excluding currency translation effects and divestments) to SEK 4,742m (3,451). Earnings were positively impacted by higher prices, a better product mix, higher volumes, lower raw material and energy costs and cost savings amounting to SEK 206m, of which SEK 202m was related to the cost-savings program. The continuous cost savings were negatively impacted by higher costs for incentive programs and pensions in addition to distribution costs. Investments to increase growth and higher costs for incentive programs

increased sales and marketing costs. Higher distribution costs and stock revaluations, due to lower raw material prices, had a negative impact on earnings.
Adjusted profit before tax increased 40% (31% excluding currency translation effects and divestments) and amounted to SEK 4,237m (3,020).
Profit for the period declined 16% (25% excluding currency translation effects and divestments) to SEK 3,046m (3,617). Earnings per share were SEK 3.87 (4.85). The adjusted earnings per share were SEK 4.10 (4.97). Profit for the period in 2018 was positively affected by a decision in a tax case in Sweden that reduced the tax cost by approximately SEK 1.1bn.
The adjusted return on capital employed was 16.4% (12.7). The adjusted return on equity was 19.9% (26.7).
January–December 2019 compared with the corresponding period a year ago The operating cash surplus amounted to SEK 22,932m (18,570). The cash flow effect of changes in working capital was SEK 359m (-971). Investments in non-current assets, net, excluding investments in operating assets through leases, amounted to SEK -5,707m (-6,781). Operating cash flow before investments in operating assets through leases amounted to SEK 16,090m (9,900). Investments in operating assets through leases amounted to SEK -451m (0). Operating cash flow was SEK 15,639m (9,900).
Financial items increased to SEK -1,309m (-1,157). The increase was mainly related to higher interest and higher average net debt, primarily due to the new accounting standard for leases. Tax payments had a negative impact on cash flow of SEK -1,130m (-2,466). A decision in a tax case in Sweden reduced the tax payment by approximately SEK 1.1bn.
The net sum of acquisitions and divestments was SEK 77m (-626). Net cash flow totaled SEK 8,915m (1,307).
Net debt decreased by SEK 3,464m during the year and amounted to SEK 50,940m. Excluding pension liabilities, net debt amounted to SEK 47,915m. The new accounting standard for leases increased net debt by SEK 3,786m. Net cash flow reduced net debt by SEK 8,915m. Fair value measurement of pension assets and updated assumptions and assessments that affect measurement of the net pension liability, together with fair value measurement of financial instruments, reduced net debt by SEK 487m. Exchange rate movements increased net debt by SEK 1,718m. Investments in non-operating assets through leases increased net debt by SEK 434m.
The debt/equity ratio was 0.81 (0.99). Excluding pension liabilities, the debt/equity ratio was 0.76 (0.92). The debt payment capacity was 38% (25). Net debt in relation to adjusted EBITDA amounted to 2.25 (2.96).
The Group's equity increased by SEK 7,902m during the period, to SEK 62,801m. Net profit for the period increased equity by SEK 10,212m. Dividends to shareholders of SEK 4,374m reduced equity. Equity increased net after tax by SEK 536m as a result of fair value measurement of pension assets and updated assumptions and assessments that affect the valuation of the pension liability. Fair value measurement of financial instruments reduced equity by SEK 447m after tax. Exchange rate movements, including the effect of hedges of net foreign investments, after tax, increased equity by SEK 1,954m. Other items increased equity by SEK 21m.

A tax expense of SEK 2,987m was reported, excluding items affecting comparability. The reported tax expense corresponds to a tax rate of about 21.7% for the period. The tax expense including items affecting comparability was SEK 2,828m, corresponding to a tax rate of 21.7% for the period. A revaluation of deferred tax had a positive impact on the tax rate of SEK 253m in the second quarter of 2019.
The Board of Directors proposes an increase in the dividend of 9% to SEK 6.25 (5.75) per share or SEK 4,390m (4,038). April 6, 2020 is proposed as the record date for the right to receive dividends.


Share of Group, adjusted EBITA 1912


0 2 4 6 8 10 12 14 16 0 200 400 600 800 1,000 1,200 1,400 1,600 1,800 Adjusted EBITA and margin SEKm %
| 1912 vs 1812 |
19:4 vs 18:4 |
|
|---|---|---|
| Total | 6.6 | 6.2 |
| Price/mix | 1.1 | 0.6 |
| Volume | 2.3 | 1.9 |
| Currency | 3.6 | 4.5 |
| Acquisitions | 0.1 | 0.0 |
| Divestments | -0.5 | -0.8 |
| 1912 vs 1812 |
19:4 vs 18:4 |
|
|---|---|---|
| Total | 6 | 6 |
| Price/mix | 7 | 1 |
| Volume | 8 | 6 |
| Raw materials | -7 | 9 |
| Energy | -1 | 0 |
| Currency | 5 | 7 |
| Other | -6 | -17 |
| SEKm | 1912 | 1812 | % | 2019:4 | 2018:4 | % |
|---|---|---|---|---|---|---|
| Net sales | 48,340 | 45,342 | 7 | 12,425 | 11,703 | 6 |
| Adjusted EBITA* | 6,746 | 6,354 | 6 | 1,756 | 1,652 | 6 |
| Adjusted EBITA margin, %* | 14.0 | 14.0 | 14.1 | 14.1 | ||
| Adjusted operating profit* | 6,014 | 5,663 | 6 | 1,567 | 1,470 | 7 |
| Adjusted operating margin, %* | 12.4 | 12.5 | 12.6 | 12.6 | ||
| Adjusted return on capital employed, %* | 15.2 | 15.3 | 15.6 | 15.8 | ||
| Operating cash flow | 6,495 | 5,006 | 1,643 | 1,244 |
*) Excluding restructuring costs, which are reported as items affecting comparability outside of the business area.
Net sales increased 6.6% to SEK 48,340m (45,342). Organic net sales, which exclude exchange rate effects, acquisitions and divestments, increased 3.4%, of which volume accounted for 2.3% and price/mix for 1.1%. Organic net sales in mature markets increased 1.6%. In emerging markets, which accounted for 37% of net sales, organic net sales increased 7.0%. Acquisitions in Latin America increased net sales by 0.1%. Exchange rate effects increased net sales by 3.6%. The divestment of the jointly owned company SCA Yildiz in Turkey reduced net sales by 0.5%.
For Incontinence Products, with the globally leading TENA brand, organic net sales increased 5.0%. Growth was related to Western Europe, North America and emerging markets. In Medical Solutions, organic net sales increased 0.5%, mainly related to emerging markets and Western Europe. For Baby Care, organic net sales decreased 1.2% related to emerging markets. Organic net sales increased in Western Europe. For Feminine Care, organic net sales increased 9.4%, related to Latin America, Western Europe and Asia.
Adjusted operating profit before amortization of acquisition-related intangible assets (adjusted EBITA), increased 6% (1% excluding currency translation effects, acquisitions and divestments) to SEK 6,746m (6,354). The increase was mainly related to higher prices, a better mix, higher volumes and cost savings. Higher raw material and energy costs negatively impacted profit by SEK -509m, which corresponds to a negative impact on the adjusted EBITA margin of -1.1 percentage points. The significantly higher raw material costs were mainly related to pulp and a negative currency transaction effect. Higher distribution costs also negatively impacted earnings. Investments to increase growth and costs for implementation of the Medical Device Regulation resulted in higher sales and marketing costs.
The operating cash surplus amounted to SEK 8,785m (7,821).
Net sales increased 6.2% to SEK 12,425m (11,703). Organic net sales, which exclude exchange rate effects, acquisitions and divestments, increased 2.5%, of which volume accounted for 1.9% and price/mix for 0.6%. Organic net sales in mature markets increased 0.1%. In emerging markets, which accounted for 37% of net sales, organic net sales increased 6.9%. Exchange rate effects increased net sales by 4.5%. The divestment of the jointly owned company SCA Yildiz in Turkey reduced net sales by 0.8%.
-6 For Incontinence Products, with the globally leading TENA brand, organic net sales increased 4.6%. Growth was related to Western Europe and emerging markets. In Medical Solutions, organic net sales decreased 0.1%, mainly related to North America. For Baby Care, organic net sales decreased 3.4% related to Russia, Western Europe and Latin America. For Feminine Care, organic net sales increased 8.0%. The increase was related to Latin America and Western Europe.
Adjusted operating profit before amortization of acquisition-related intangible assets (adjusted EBITA), increased 6% (declined 2% excluding currency translation effects and divestments) to SEK 1,756m (1,652). The increase was mainly related to higher prices, a better mix, higher volumes, lower raw material costs and cost savings. Higher distribution costs negatively impacted earnings. Investments to increase growth and costs for implementation of the Medical Device Regulation resulted in higher sales and marketing costs.






Change in net sales (%)
| 1912 vs 1812 |
19:4 vs 18:4 |
|
|---|---|---|
| Total | 10.6 | 9.7 |
| Price/mix | 3.2 | 1.3 |
| Volume | 2.9 | 3.6 |
| Currency | 4.4 | 4.8 |
| Acquisitions | 0.1 | 0.0 |
| Divestments | 0.0 | 0.0 |
| 1912 vs 1812 |
19:4 vs 18:4 |
|
|---|---|---|
| Total | 60 | 110 |
| Price/mix | 44 | 19 |
| Volume | 12 | 12 |
| Raw materials | 24 | 116 |
| Energy | 1 | 12 |
| Currency | 8 | 9 |
| Other | -29 | -58 |
| SEKm | 1912 | 1812 | % | 2019:4 | 2018:4 | % |
|---|---|---|---|---|---|---|
| Net sales | 49,904 | 45,125 | 11 | 13,269 | 12,094 | 10 |
| Adjusted EBITA* | 5,321 | 3,331 | 60 | 1,767 | 840 | 110 |
| Adjusted EBITA margin, %* | 10.7 | 7.4 | 13.3 | 6.9 | ||
| Adjusted operating profit* | 5,314 | 3,326 | 60 | 1,765 | 836 | 111 |
| Adjusted operating margin, %* | 10.6 | 7.4 | 13.3 | 6.9 | ||
| Adjusted return on capital employed, %* | 11.2 | 7.4 | 14.8 | 7.4 | ||
| Operating cash flow | 4,870 | 2,388 | 1,857 | 1,503 |
*) Excluding restructuring costs, which are reported as items affecting comparability outside of the business area.
Net sales increased 10.6% to SEK 49,904m (45,125). Organic net sales, which exclude exchange rate effects, acquisitions and divestments, increased 6.1%, of which volume accounted for 2.9% and price/mix for 3.2%. Excluding lower sales of mother reels resulting from production closures within the scope of Tissue Roadmap, organic net sales increased 6.6%. Organic net sales increased 2.6% in mature markets. In emerging markets, which accounted for 47% of net sales, organic net sales increased by 10.7%. Acquisitions in Latin America increased net sales by 0.1%. Exchange rate effects increased net sales by 4.4%.
Adjusted operating profit before amortization of acquisition-related intangible assets (adjusted EBITA) increased 60% (52% excluding currency translation effects and acquisitions) to SEK 5,321m (3,331). The increase was mainly due to higher prices, a better mix, higher volumes, lower raw material and energy costs, and cost savings. Stock revaluations, due to lower raw material prices, and higher distribution costs had a negative impact on earnings. Investments to increase growth resulted in higher sales and marketing costs.
The operating cash surplus totaled SEK 8,107m (5,612).
Net sales increased 9.7% to SEK 13,269m (12,094). Organic net sales, which exclude exchange rate effects, acquisitions and divestments, increased 4.9%. Volumes increased by 3.6%, mainly related to Asia and Latin America. Price/mix increased 1.3%, primarily related to Europe and Latin America. Organic net sales increased 3.6% in mature markets. In emerging markets, which accounted for 48% of net sales, organic net sales increased by 6.5%. Exchange rate effects increased net sales by 4.8%.
Adjusted operating profit before amortization of acquisition-related intangible assets (adjusted EBITA) increased 110% (101% excluding currency translation effects) to SEK 1,767m (840). A better price/mix, higher volumes, lower raw material and energy costs and cost savings had a positive impact on earnings. Stock revaluations, due to lower raw material prices had a negative impact on earnings. Investments to increase growth resulted in higher sales and marketing costs.
-6





| Change in net sales (%) | |||
|---|---|---|---|
| 1912 vs | 19:4 vs | |
|---|---|---|
| 1812 | 18:4 | |
| Total | 9.7 | 9.1 |
| Price/mix | 2.1 | 2.3 |
| Volume | 1.5 | 0.7 |
| Currency | 6.1 | 6.1 |
| Acquisitions | 0.0 | 0.0 |
| Divestments | 0.0 | 0.0 |
| 1912 vs 1812 |
19:4 vs 18:4 |
|
|---|---|---|
| Total | 16 | 30 |
| Price/mix | 13 | 12 |
| Volume | 4 | 1 |
| Raw materials | 11 | 34 |
| Energy | 0 | 1 |
| Currency | 6 | 8 |
| Other | -18 | -26 |
| SEKm | 1912 | 1812 | % | 2019:4 | 2018:4 | % |
|---|---|---|---|---|---|---|
| Net sales | 30,731 | 28,017 | 10 | 7,991 | 7,322 | 9 |
| Adjusted EBITA* | 4,463 | 3,841 | 16 | 1,408 | 1,085 | 30 |
| Adjusted EBITA margin, %* | 14.5 | 13.7 | 17.6 | 14.8 | ||
| Adjusted operating profit* | 4,424 | 3,805 | 16 | 1,398 | 1,076 | 30 |
| Adjusted operating margin, %* | 14.4 | 13.6 | 17.5 | 14.7 | ||
| Adjusted return on capital employed, %* | 18.9 | 18.1 | 23.8 | 20.0 | ||
| Operating cash flow | 4,938 | 3,363 | 1,623 | 891 |
*) Excluding restructuring costs, which are reported as items affecting comparability outside of the business area.
Net sales increased 9.7% to SEK 30,731m (28,017). Organic net sales, which exclude exchange rate effects, acquisitions and divestments, increased 3.6%, of which volume accounted for 1.5% and price/mix for 2.1%. Organic net sales increased 2.2% in mature markets. In emerging markets, which accounted for 20% of net sales, organic net sales increased 9.9%. Exchange rate effects increased net sales by 6.1%.
Adjusted operating profit before amortization of acquisition-related intangible assets (adjusted EBITA) increased 16% (10% excluding currency translation effects) to SEK 4,463m (3,841). Earnings were positively impacted by higher prices, a better mix, higher volumes, lower raw material costs and cost savings. Stock revaluations, due to lower raw material prices, had a negative impact on earnings. Investments to increase growth resulted in higher sales and marketing costs.
The operating cash surplus was SEK 6,589m (5,630).
Net sales increased 9.1% to SEK 7,991m (7,322). Organic net sales, which exclude exchange rate effects, acquisitions and divestments, increased 3.0%. Volumes increased 0.7%, mainly related to Europe, Latin America and North America. Price/mix increased by 2.3%, mainly related to Europe and North America. Organic net sales increased 2.3% in mature markets. In emerging markets, which accounted for 21% of net sales, organic net sales increased 6.1%. Exchange rate effects increased net sales by 6.1%.
Adjusted operating profit before amortization of acquisition-related intangible assets (adjusted EBITA) increased 30% (22% excluding currency translation effects) to SEK 1,408m (1,085). Earnings were positively impacted by higher prices, a better mix, higher volumes, lower raw material and energy costs and cost savings. Stock revaluations, due to lower raw material prices, had a negative impact on earnings. Investments to increase growth resulted in higher sales and marketing costs. A one-off effect related to reduced pension liabilities in the US had a positive effect on earnings of approximately SEK 70m.
-6

| December 31, 2019 | Class A | Class B | Total |
|---|---|---|---|
| Registered number of shares | 63,934,642 | 638,407,847 | 702,342,489 |
At the end of the period, the proportion of Class A shares was 9.1%. No shares were converted during the period. The total number of votes in the company amounts to 1,277,754,267.
Essity's Annual Report for 2019 is intended to be published in the week beginning March 9, 2020. In 2020, interim reports will be published on April 23, July 17 and October 22.
Essity's Annual General Meeting will be held in Stockholm on April 2, 2020.
Media and analysts are invited to a press conference at which President and CEO Magnus Groth will present this Year-end Report.
Date: Wednesday, January 22, 2020 Time: 9:00 a.m. CET Location: Essity's headquarters, Waterfront Building, Klarabergsviadukten 63, Stockholm, Sweden Link to Web presentation: https://essity.videosync.fi/2020-01-22-q4
The press conference will be webcast at www.essity.com. To participate by telephone, call: +44 (0)207 192 80 00, +1 631 510 74 95 or +46 (0)8 506 921 80. Please call well in advance of the start of the conference. Specify "Essity" or conference ID no. 3561699.
Stockholm, January 22, 2020 Essity Aktiebolag (publ)
Magnus Groth President and CEO
Fredrik Rystedt, CFO and Executive Vice President, +46 (0)8 788 51 31 Johan Karlsson, Vice President Investor Relations, Group Function Communications, +46 (0)8 788 51 30 Joséphine Edwall Björklund, Senior Vice President, Group Function Communications, +46 (0)8 788 52 34 Per Lorentz, Vice President Corporate Communications, Group Function Communications, +46 (0)8 788 52 51
NB:
This information is such that Essity Aktiebolag (publ) is obligated to make public pursuant to the EU Market Abuse Regulation. This report has been prepared in both Swedish and English versions. In case of variations in the content between the two versions, the Swedish version shall govern. The information was submitted for publication, through the agency of the contact person set out below, at 07:00 CET on January 22, 2020.
Karl Stoltz, Media Relations Manager, +46 (0)8 788 51 55

| SEKm | 2019:4 | 2018:4 | 2019:3 | 1912 | 1812 |
|---|---|---|---|---|---|
| Net sales | 33,686 | 31,112 | 32,565 | 128,975 | 118,500 |
| Cost of goods sold1,2 | -22,997 | -22,574 | -22,793 | -90,876 | -85,058 |
| Items affecting comparability1 | -11 | 71 | 23 | -243 | -1,437 |
| Gross profit | 10,678 | 8,609 | 9,795 | 37,856 | 32,005 |
| Sales, general and administration1 | -5,986 | -5,106 | -5,594 | -22,319 | -20,570 |
| Items affecting comparability2 | 9 | -47 | -224 | -470 | 62 |
| Share of profits of associates and joint ventures | 39 | 19 | -2 | 60 | 63 |
| Operating profit before amortization of acquisition related intangible assets |
4,740 | 3,475 | 3,975 | 15,127 | 11,560 |
| Amortization of acquisition-related intangible assets1 | -202 | -195 | -196 | -778 | -732 |
| Items affecting comparability2 | 0 | -64 | 0 | 0 | -69 |
| Operating profit | 4,538 | 3,216 | 3,779 | 14,349 | 10,759 |
| Financial items | -303 | -236 | -320 | -1,309 | -1,157 |
| Profit before tax | 4,235 | 2,980 | 3,459 | 13,040 | 9,602 |
| Tax | -1,189 | 637 | -723 | -2,828 | -1,050 |
| Profit for the period | 3,046 | 3,617 | 2,736 | 10,212 | 8,552 |
| Earnings attributable to: | |||||
| Owners of the parent | 2,716 | 3,403 | 2,477 | 9,216 | 7,886 |
| Non-controlling interests | 330 | 214 | 259 | 996 | 666 |
| Average no. of shares before dilution, millions | 702.3 | 702.3 | 702.3 | 702.3 | 702.3 |
| Average no. of shares after dilution, millions | 702.3 | 702.3 | 702.3 | 702.3 | 702.3 |
| Earnings per share, SEK - owners of the parent | |||||
| - before dilution effects | 3.87 | 4.85 | 3.53 | 13.12 | 11.23 |
| - after dilution effects | 3.87 | 4.85 | 3.53 | 13.12 | 11.23 |
| 1Of which, depreciation | -1,925 | -1,611 | -1,879 | -7,477 | -6,175 |
| 2Of which, impairment | -58 | 23 | 72 | -52 | -533 |
| Gross margin | 31.7 | 27.7 | 30.1 | 29.4 | 27.0 |
| EBITA margin | 14.1 | 11.2 | 12.2 | 11.7 | 9.8 |
| Operating margin | 13.5 | 10.3 | 11.6 | 11.1 | 9.1 |
| Financial net margin | -0.9 | -0.8 | -1.0 | -1.0 | -1.0 |
| Profit margin | 12.6 | 9.5 | 10.6 | 10.1 | 8.1 |
| Tax | -3.5 | 2.0 | -2.2 | -2.2 | -0.9 |
| Net margin | 9.1 | 11.5 | 8.4 | 7.9 | 7.2 |
| Excluding items affecting comparability: | |||||
| Gross margin | 31.7 | 27.4 | 30.0 | 29.5 | 28.2 |
| EBITA margin | 14.1 | 11.1 | 12.8 | 12.3 | 10.9 |
| Operating margin | 13.5 | 10.5 | 12.2 | 11.7 | 10.3 |
| Financial net margin | -0.9 | -0.8 | -1.0 | -1.0 | -1.0 |
| Profit margin | 12.6 | 9.7 | 11.2 | 10.7 | 9.3 |
| Tax | -3.5 | 1.9 | -2.2 | -2.3 | -1.3 |
| Net margin | 9.1 | 11.6 | 9.0 | 8.4 | 8.0 |

| SEKm | 2019:4 | 2018:4 | 2019:3 | 1912 | 1812 |
|---|---|---|---|---|---|
| Profit for the period | 3,046 | 3,617 | 2,736 | 10,212 | 8,552 |
| Other comprehensive income for the period | |||||
| Items that may not be reclassified to the income statement | |||||
| Actuarial gains/losses on defined benefit pension plans | 2,486 | -2,196 | -1,169 | 482 | -1,036 |
| Measured at fair value through other comprehensive income | 0 | -4 | 1 | 6 | -5 |
| Income tax attributable to components of other comprehensive income | -392 | 459 | 222 | 52 | 176 |
| 2,094 | -1,741 | -946 | 540 | -865 | |
| Items that have been or may be reclassified subsequently to the income statement | |||||
| Cash flow hedges | -267 | -303 | 58 | -613 | 93 |
| Translation differences in foreign operations | -2,359 | -559 | 1,967 | 2,095 | 2,080 |
| Gains/losses from hedges of net investments in foreign operations | 189 | 300 | -146 | -168 | -122 |
| Other comprehensive income from associated companies | 1 | 13 | -5 | -14 | 23 |
| Income tax attributable to components of other comprehensive income | 25 | 10 | 16 | 179 | 4 |
| -2,411 | -539 | 1,890 | 1,479 | 2,078 | |
| Other comprehensive income for the period, net of tax | -317 | -2,280 | 944 | 2,019 | 1,213 |
| Total comprehensive income for the period | 2,729 | 1,337 | 3,680 | 12,231 | 9,765 |
| Total comprehensive income attributable to: | |||||
| Owners of the parent | 2,687 | 1,166 | 3,213 | 11,006 | 8,893 |
| Non-controlling interests | 42 | 171 | 467 | 1,225 | 872 |
| SEKm | 1912 | 1812 |
|---|---|---|
| Attributable to owners of the parent | ||
| Opening balance, January 1 | 47,141 | 42,289 |
| Effect attributable to change accounting standard IFRS 9 | 0 | -9 |
| Tax effect attributable to change accounting standard IFRS 9 | 0 | 2 |
| Total comprehensive income for the period | 11,006 | 8,893 |
| Dividend | -4,038 | -4,038 |
| Private placement to non-controlling interest | 2 | 3 |
| Transferred to cost of hedged investment | 14 | 1 |
| Closing balance | 54,125 | 47,141 |
| Non-controlling interests | ||
| Opening balance, January 1 | 7,758 | 7,281 |
| Total comprehensive income for the period | 1,225 | 872 |
| Disposal of non-controlling interest | 27 | - |
| Dividend | -336 | -397 |
| Private placement to non-controlling interest | 2 | 2 |
| Closing balance | 8,676 | 7,758 |
| Total equity, closing balance | 62,801 | 54,899 |

| SEKm | 1912 | 1812 |
|---|---|---|
| Operating cash surplus | 22,932 | 18,570 |
| Change in working capital | 359 | -971 |
| Capital expenditures non current assets, net | -5,707 | -6,781 |
| Restructuring costs, etc. | -1,494 | -918 |
| Operating cash flow before Investments in operating assets through leases | 16,090 | 9,900 |
| Investments in operating assets through leases | -451 | 0 |
| Operating cash flow | 15,639 | 9,900 |
| Financial items | -1,309 | -1,157 |
| Income taxes paid | -1,130 | -2,466 |
| Other | 8 | 86 |
| Cash flow from current operations | 13,208 | 6,363 |
| Acquisitions | -143 | -694 |
| Divestments | 220 | 68 |
| Cash flow before dividend | 13,285 | 5,737 |
| Private placement to non-controlling interest | 4 | 5 |
| Dividend to non-controlling interests | -336 | -397 |
| Dividend | -4,038 | -4,038 |
| Net cash flow | 8,915 | 1,307 |
| Net debt at the start of the period | -54,404 | -52,467 |
| Changed opening balance for net debt due to IFRS 16 Leases | -3,786 | 0 |
| Net cash flow | 8,915 | 1,307 |
| Remeasurement to equity | 487 | -1,042 |
| Investments in non-operating assets through leases | -434 | 0 |
| Translation differences | -1,718 | -2,202 |
| Net debt at the end of the period | -50,940 | -54,404 |
| Debt/equity ratio | 0.81 | 0.99 |
| Debt payment capacity, % | 38 | 25 |
| Net debt / EBITDA | 2.33 | 3.11 |
| Net debt / Adjusted EBITDA | 2.25 | 2.96 |
As of 2019, strategic capital expenditures are recognized together with current capital expenditures and included in Investments in non-current assets, net. Previously, strategic capital expenditures were recognized under cash flow from current operations together with acquisitions and divestments. The effect of the restatement of comparative periods entailed a decrease in Operating cash flow and Cash flow from current operations of SEK -2,424m for full-year 2018. Net cash flow is unchanged for periods in the preceding year.
Investments in operating assets through leases are recognized separately and subtotals for operating cash flow before and after these investments have been introduced into the operating cash flow statement. Investments in non-operating assets through leases do not constitute part of operating cash flow but are instead recognized as a change in net debt. The initial effect of the transition to IFRS 16 is also recognized on a line in change in net debt.

| SEKm | 1912 | 1812 |
|---|---|---|
| Operating activities | ||
| Operating profit | 14,349 | 10,759 |
| Adjustment for non-cash items1 | 8,193 | 7,562 |
| Interest paid | -1,010 | -818 |
| Interest received | 105 | 85 |
| Other financial items | -420 | -408 |
| Change in liabilities relating to restructuring programs, etc. | -1,095 | -583 |
| Paid tax | -1,130 | -2,466 |
| Cash flow from operating activities | ||
| before changes in working capital | 18,992 | 14,131 |
| Cash flow from changes in working capital | ||
| Change in inventories | -194 | -1,017 |
| Change in operating receivables | -1,949 | -344 |
| Change in operating liabilities | 2,502 | 390 |
| Cash flow from operating activities | 19,351 | 13,160 |
| Investing activities | ||
| Company acquisitions | -143 | -461 |
| Divestments | 5 | 68 |
| Investments in property, plant and equipment and intangible assets | -5,908 | -6,882 |
| Sale of property, plant and equipment | 239 | 134 |
| Loans granted to external parties | -62 | 0 |
| Repayment of loans from external parties | 0 | 178 |
| Paid interest capitalized in property, plant and equipment and intangible assets | -39 | -24 |
| Cash flow from investing activities | -5,908 | -6,987 |
| Financing activities | ||
| Private placement to non-controlling interests | 4 | 5 |
| Dividend | -4,038 | -4,038 |
| Loans raised | 2,448 | 4,386 |
| Amortization of debt | -11,708 | -7,295 |
| Dividend to non-controlling interests | -336 | -397 |
| Cash flow from financing activities | -13,630 | -7,339 |
| Cash flow for the period | -187 | -1,166 |
| Cash and cash equivalents at the beginning of the period | 3,008 | 4,107 |
| Exchange -differences in cash and cash equivalents | 107 | 67 |
| Cash and cash equivalents at the end of the period | 2,928 | 3,008 |
| Cash flow from operating activities per share, SEK | 27.55 | 18.74 |

| SEKm | 1912 | 1812 |
|---|---|---|
| Reconciliation with consolidated operating cash flow statement | ||
| Cash flow for the period | -187 | -1,166 |
| Amortization of debt | 11,708 | 7,295 |
| Loans raised | -2,448 | -4,386 |
| Loans granted to external parties | 62 | 0 |
| Repayment of loans from external parties | 0 | -178 |
| Investment through financial lease | -451 | -8 |
| Net debt in acquired and divested operations | 215 | -234 |
| Accrued interest | 17 | -16 |
| Other | -1 | 0 |
| Net cash flow according to consolidated operating cash flow statement | 8,915 | 1,307 |
| 1) Adjustment for non-cash items | ||
| Depreciation/amortization and impairment of non-current assets | 7,529 | 6,709 |
| Gain/loss on asset sales and swaps | 24 | 35 |
| Change, provision related to antitrust cases | 0 | 95 |
| Gain/loss on divestments | 160 | -69 |
| Unpaid relating to efficiency program | 128 | 669 |
| Change, one-time foreign tax on non-current assets | 0 | -288 |
| Share of profits of associated companies, items affecting comparability (Asaleo Care Ltd) | 0 | 278 |
| Revaluation effect of previously owned holding upon acquisition | 0 | -225 |
| Other | 352 | 358 |
| Total | 8,193 | 7,562 |
Until 2018, payments were recognized for pension plans with a surplus in cash flow from investing activities and payments for pension plans with a deficit in cash flow from Financing activities. From 2019, all payments for pensions are recognized in cash flow from Financing activities given that Essity has a net pension liability. The change means that the comparative period, fullyear 2018, was restated, which is why cash flow from Investing activities was changed by SEK +439m and cash flow from Financing activities was changed by SEK -439m compared with the figures presented in the year-end report for 2018. Cash flow from operating activities is unchanged for the periods.

| SEKm | December 31, 2019 | December 31, 2018 |
|---|---|---|
| Assets | ||
| Goodwill | 34,581 | 33,553 |
| Other intangible assets | 21,182 | 21,475 |
| Buildings, land, machinery and equipment | 56,900 | 51,673 |
| Participation in joint ventures and associates | 865 | 777 |
| Shares and participation | 8 | 29 |
| Surplus in funded pension plans | 2,841 | 1,117 |
| Non-current financial assets | 694 | 634 |
| Deferred tax assets | 2,539 | 2,158 |
| Other non-current assets | 704 | 705 |
| Total non-current assets | 120,314 | 112,121 |
| Inventories | 15,764 | 15,234 |
| Trade receivables | 19,864 | 18,687 |
| Current tax assets | 745 | 2,126 |
| Other current receivables | 2,113 | 2,599 |
| Current financial assets | 525 | 422 |
| Non-current assets held for sale | 42 | 69 |
| Cash and cash equivalents | 2,928 | 3,008 |
| Total current assets | 41,981 | 42,145 |
| Total assets | 162,295 | 154,266 |
| Equity | ||
| Share capital | 2,350 | 2,350 |
| Reserves | 6,284 | 5,003 |
| Retained earnings | 45,491 | 39,788 |
| Attributable to owner of the Parent | 54,125 | 47,141 |
| Non-controlling interests | 8,676 | 7,758 |
| Total equity | 62,801 | 54,899 |
| Liabilities | ||
| Non-current financial liabilities | 43,079 | 43,500 |
| Provisions for pensions | 5,866 | 5,258 |
| Deferred tax liabilities | 6,545 | 7,272 |
| Other non-current provisions | 541 | 1,694 |
| Other non-current liabilities | 183 | 71 |
| Total non-current liabilities | 56,214 | 57,795 |
| Current financial liabilities | 8,983 | 10,827 |
| Trade payables | 15,802 | 15,911 |
| Current tax liabilities | 2,432 | 570 |
| Current provisions | 1,065 | 1,472 |
| Other current liabilities | 14,998 | 12,792 |
| Total current liabilities | 43,280 | 41,572 |
| Total liabilities | 99,494 | 99,367 |
| Total equity and liabilities | 162,295 | 154,266 |

| SEKm | December 31, 2019 | December 31, 2018 |
|---|---|---|
| Debt/equity ratio | 0.81 | 0.99 |
| Equity/assets ratio | 33% | 31% |
| Equity | 62,801 | 54,899 |
| Equity per share | 89 | 78 |
| Return on equity | 17.4% | 16.1% |
| Return on equity excluding items affecting comparability | 18.4% | 18.0% |
| Capital employed | 113,741 | 109,303 |
| - of which working capital | 6,782 | 7,568 |
| Return on capital employed* | 13.2% | 10.8% |
| Return on capital employed* excluding items affecting comparability | 13.8% | 12.0% |
| Net debt | 50,940 | 54,404 |
| Provisions for restructuring costs are included in the balance sheet as follows | ||
| -Other non-current provisions | 184 | 118 |
| -Other current provisions | 603 | 905 |
| Provisions for tax risks are included in the balance sheet as follows | ||
| -Other non-current provisions | 0 | 701 |
| -Other current provisions | 0 | 12 |
*) rolling 12 months

| SEKm | 1912 | 1812 | 2019:4 | 2019:3 | 2019:2 | 2019:1 | 2018:4 | 2018:3 |
|---|---|---|---|---|---|---|---|---|
| Personal Care | 48,340 | 45,342 | 12,425 | 12,216 | 12,164 | 11,535 | 11,703 | 11,408 |
| Consumer Tissue | 49,904 | 45,125 | 13,269 | 12,220 | 12,167 | 12,248 | 12,094 | 10,912 |
| Professional Hygiene | 30,731 | 28,017 | 7,991 | 8,131 | 7,742 | 6,867 | 7,322 | 7,309 |
| Other | 0 | 16 | 1 | -2 | -5 | 6 | -7 | 18 |
| Total net sales | 128,975 | 118,500 | 33,686 | 32,565 | 32,068 | 30,656 | 31,112 | 29,647 |
| SEKm | 1912 | 1812 | 2019:4 | 2019:3 | 2019:2 | 2019:1 | 2018:4 | 2018:3 |
|---|---|---|---|---|---|---|---|---|
| Personal Care | 6,746 | 6,354 | 1,756 | 1,739 | 1,711 | 1,540 | 1,652 | 1,565 |
| Consumer Tissue | 5,321 | 3,331 | 1,767 | 1,319 | 1,166 | 1,069 | 840 | 635 |
| Professional Hygiene | 4,463 | 3,841 | 1,408 | 1,288 | 1,026 | 741 | 1,085 | 970 |
| Other | -690 | -591 | -189 | -170 | -171 | -160 | -126 | -154 |
| Total adjusted EBITA | 15,840 | 12,935 | 4,742 | 4,176 | 3,732 | 3,190 | 3,451 | 3,016 |
| 1912 | 1812 | 2019:4 | |||||
|---|---|---|---|---|---|---|---|
| 2019:3 | 2019:2 | 2019:1 | 2018:4 | 2018:3 | |||
| 6,014 | 5,663 | 1,567 | 1,554 | 1,529 | 1,364 | 1,470 | 1,387 |
| 5,314 | 3,326 | 1,765 | 1,317 | 1,164 | 1,068 | 836 | 635 |
| 4,424 | 3,805 | 1,398 | 1,278 | 1,016 | 732 | 1,076 | 960 |
| -690 | -591 | -190 | -169 | -170 | -161 | -126 | -153 |
| 15,062 | 12,203 | 4,540 | 3,980 | 3,539 | 3,003 | 3,256 | 2,829 |
| -1,309 | -1,157 | -303 | -320 | -344 | -342 | -236 | -332 |
| 13,753 | 11,046 | 4,237 | 3,660 | 3,195 | 2,661 | 3,020 | 2,497 |
| -2,987 | -1,490 | -1,178 | -730 | -482 | -597 | 602 | -670 |
| 10,766 | 9,556 | 3,059 | 2,930 | 2,713 | 2,064 | 3,622 | 1,827 |
| -713 | -1,444 | -2 | -201 | -322 | -188 | -40 | -1,016 |
| -554 | -1,004 | -13 | -194 | -212 | -135 | -5 | -749 |
| % | 1912 | 1812 | 2019:4 | 2019:3 | 2019:2 | 2019:1 | 2018:4 | 2018:3 |
|---|---|---|---|---|---|---|---|---|
| Personal Care | 14.0 14.0 |
14.1 | 14.2 | 14.1 | 13.4 | 14.1 | 13.7 | |
| Consumer Tissue | 10.7 7.4 |
13.3 | 10.8 | 9.6 | 8.7 | 6.9 | 5.8 | |
| Professional Hygiene | 14.5 13.7 |
17.6 | 15.8 | 13.3 | 10.8 | 14.8 | 13.3 |
| SEKm | 2019:4 | 2019:3 | 2019:2 | 2019:1 | 2018:4 |
|---|---|---|---|---|---|
| Net sales | 33,686 | 32,565 | 32,068 | 30,656 | 31,112 |
| Cost of goods sold | -22,997 | -22,793 | -22,779 | -22,307 | -22,574 |
| Items affecting comparability | -11 | 23 | -156 | -99 | 71 |
| Gross profit | 10,678 | 9,795 | 9,133 | 8,250 | 8,609 |
| Sales, general and administration | -5,986 | -5,594 | -5,553 | -5,186 | -5,106 |
| Items affecting comparability | 9 | -224 | -166 | -89 | -47 |
| Share of profits of associates and joint ventures | 39 | -2 | -4 | 27 | 19 |
| EBITA | 4,740 | 3,975 | 3,410 | 3,002 | 3,475 |
| Amortization of acquisition-related intangible assets | -202 | -196 | -193 | -187 | -195 |
| Items affecting comparability | 0 | 0 | 0 | 0 | -64 |
| Operating profit | 4,538 | 3,779 | 3,217 | 2,815 | 3,216 |
| Financial items | -303 | -320 | -344 | -342 | -236 |
| Profit before tax | 4,235 | 3,459 | 2,873 | 2,473 | 2,980 |
| Taxes | -1,189 | -723 | -372 | -544 | 637 |
| Net profit for the period | 3,046 | 2,736 | 2,501 | 1,929 | 3,617 |

| SEKm | 1912 | 1812 |
|---|---|---|
| Administrative expenses | -663 | -738 |
| Other operating income | 209 | 192 |
| Operating loss | -454 | -546 |
| Financial items | 4,552 | 17,648 |
| Profit before tax | 4,098 | 17,102 |
| Appropriations and tax on profit for the period | 24 | -940 |
| Profit for the period | 4,122 | 16,162 |
| SEKm | December 31, 2019 | December 31, 2018 |
|---|---|---|
| Intangible fixed assets | 0 | 0 |
| Tangible fixed assets | 16 | 5 |
| Financial fixed assets | 176,352 | 175,447 |
| Total fixed assets | 176,368 | 175,452 |
| Total current assets | 1,794 | 3,041 |
| Total assets | 178,162 | 178,493 |
| Restricted equity | 2,350 | 2,350 |
| Unrestricted equity | 87,942 | 87,859 |
| Total equity | 90,292 | 90,209 |
| Untaxed reserves | 4 | 1 |
| Provisions | 877 | 879 |
| Non-current liabilities | 36,386 | 39,226 |
| Current liabilities | 50,603 | 48,178 |
| Total equity, provisions and liabilities | 178,162 | 178,493 |

This Year-end Report has been prepared in accordance with IAS 34 and recommendation RFR 1 of the Swedish Financial Reporting Board (RFR), and with regards to the Parent Company, RFR 2.
Effective January 1, 2019, Essity applies the following new or amended International Financial Reporting Standards (IFRS):
When the standard became effective on January 1, 2019, Essity applied the modified retrospective approach, entailing an adjustment of the opening balances with the cumulative effect of initially applying the standard on the first date of initial application and that no comparative years were restated.
The lease liability is measured at the present value of the outstanding lease payments and the right-of-use asset for all leases totals an amount corresponding to the lease liability, adjusted for any prepaid lease payments and accrued lease payments recognized on December 31, 2018. For onerous leases, Essity chose in connection with the transition to IFRS 16 to utilize the option to adjust the value of the right-of-use asset downward in an amount corresponding to the estimates of onerous leases carried out in accordance with IAS 37 for the operating leases. Provisions for onerous contracts were recognized in the year-end accounts for 2018 as non-current and current provisions. This practical solution was applied as a substitute for an impairment test upon transition to IFRS 16. An impairment test will subsequently be applied by the company. An incremental borrowing rate has been set for each currency. The average incremental borrowing rate on January 1, 2019 was approximately 3%. The transition does not have any impact on equity.
Essity has decided to apply the exemption rules for short-term leases and leases where the underlying asset has a low value. These leases are not included in the right-of-use asset or the liability. In its application of the standard, Essity has determined that a time horizon of five years can generally be applied to leases of offices and distribution centers with no fixed end date even if the formal lease term is shorter.
| SEKm | Properties | Vehicles | Other | Total | Lease liabilities |
|---|---|---|---|---|---|
| Opening balance, Jan 1, 2019 as stated in AR 2018 | - | - | - | 3,694 | 3,684 |
| Adjusted opening balance | 87 | 102 | |||
| Adjusted opening balance | 3,357 | 410 | 14 | 3,781 | 3,786 |
| Additional rights of use, net | 716 | 159 | 10 | 885 | 885 |
| Leases, divestments | -46 | - | - | -46 | -46 |
| Depreciation | -656 | -221 | -7 | -884 | - |
| Interest expenses | - | - | - | - | 110 |
| Payments | - | - | - | - | -948 |
| Translation differences | 75 | 10 | 0 | 85 | 85 |
| Value at end of period | 3,446 | 358 | 17 | 3,821 | 3,872 |
| Lease liabilities consist of: | |
|---|---|
| Short-term component | 851 |
| Long-term component | 3,021 |
During the period, SEK 255m was recognized relating to costs for short-term leases, leases of low-value assets and variable lease payments.
When the standard became effective on January 1, 2019, the following adjustments were recognized in Essity's balance sheet. The right-of-use assets largely comprise leases for offices and distribution centers:

| Effect of IFRS 16, SEKm | Opening balance, January 1, 2019 |
|---|---|
| Right-of-use asset | 3,781 |
| Non-current lease liability | 3,146 |
| Current financial lease liabilities | 640 |
| Provisions (reclassification to right-of-use | |
| asset) | 30 |
| Prepaid and accrued lease payments | |
| (reclassification to right-of-use asset) | |
| 25 |
| Operating future minimum lease payments, December 31, 2018, according to Note G2, page | 3,967 |
|---|---|
| 105 of AR 2018 | |
| Present-value calculated with the Group's incremental borrowing rate at January 1, 2019 | -486 |
| Excluding short-term leases and leases with a low value | -10 |
| Renewal options that are expected to be utilized | 213 |
| Lease liability, January 1, 2019, according to AR 2018 | 3,684 |
| Adjustment of lease liability, January 1, 2019 | 102 |
| Adjusted lease liability, January 1, 2019 | 3,786 |
Upon signing a contract, it is first determined whether the contract constitutes, or contains, a lease. A contract constitutes, or contains, a lease if:
If all of the conditions above are not fulfilled, the contract is not considered to constitute, or contain, a lease and is thus classified as a service contract.
At the beginning of a lease, meaning when the asset is available for use by Essity, a right-of-use asset and a financial liability are recognized in the balance sheet.
The right-of-use asset is measured at cost and includes the following:
The right-of-use asset is recognized under the heading Buildings, land, machinery and equipment in the category non-current assets and is depreciated on a straight-line basis over the shorter period of the asset's anticipated useful life and the lease term. The useful life is assessed on the basis of the term of the underlying contract, taking into account termination and renewal clauses.
The lease liability is measured at the present value of the following lease payments:
The lease payments are normally discounted using the incremental borrowing rate since the interest rate implicit in the leases generally cannot be readily determined. The incremental borrowing rate applied is determined on the basis of the contract currency in the agreement and the lease duration.
The lease liability is recognized in the balance sheet under the headings non-current financial liabilities and current financial liabilities. Lease liabilities due within 12 months are classified as current liabilities, while those due after 12 months are classified as non-current liabilities. The lease liability is recognized at amortized cost in accordance with the effective interest method. The liability is remeasured when future payments are changed through an index or in another manner, for example if a new assessment is made of future residual value obligations or the exercise of

purchase, renewal or termination options. When the lease liability is remeasured in accordance with the above, a corresponding adjustment is made to the value of the right-of-use asset. Lease payments are allocated between interest expense and amortization of the outstanding lease liability.
Essity has decided to apply the exemption rules for short-term leases and leases where the underlying asset has a low value. These leases are not included in the right-of-use asset or the liability. Lease payments for these contracts are expensed on a straight-line basis over the useful life.
In 2017, a new interpretation was issued regarding the recognition of taxes, IFRIC 23. The interpretation clarifies how the recognition and measurement of uncertain tax items are to be conducted. Essity applied the modified retrospective approach, meaning that comparative figures were not restated. On account of IFRIC 23, Essity reclassified SEK 713m in current and non-current provisions for tax liabilities in the opening balance for 2019.
In other respects, the accounting principles and calculation methods applied correspond to those described in Essity's 2018 Annual Report.
Essity's risk exposure and risk management are described on pages 33-38 of the 2018 Annual Report for Essity. No significant changes have taken place that have affected the reported risks.
Risks in conjunction with company acquisitions are analyzed in the due diligence processes that Essity carries out prior to all acquisitions. In cases where acquisitions have been carried out that may affect the assessment of Essity's risk exposure, these are described under the heading "Other events" in the interim and year-end reports.
Essity's Board of Directors determines the Group's strategic direction based on recommendations from the Executive Management Team. Responsibility for the long-term, overall management of strategic risks corresponds to the company's delegation structure, from the Board of Directors to the CEO and from the CEO to the business unit presidents. This means that most operational risks are managed by Essity's business units at the local level, but that they are coordinated when considered necessary. The tools used in this coordination consist primarily of the business units' regular reporting and the annual strategy process, where risks and risk management are a part of the process.
Essity's financial risk management is centralized, as is the Group's internal bank for the Group companies' financial transactions and management of the Group's energy risks. Financial risks are managed in accordance with the Group's finance policy, which is adopted by Essity's Board of Directors and which – together with Essity's energy risk policy – makes up a framework for risk management. Risks are aggregated and monitored on a regular basis to ensure compliance with these guidelines. Essity has also centralized other risk management.
Essity has a staff function for internal audit, which monitors compliance in the organization with the Group's policies.

Distribution by level for measurement at fair value
| SEKm | Carrying amount in the balance sheet |
Measured at fair value through profit or loss |
Derivatives used for hedge accounting |
Measured at fair value through OCI |
Financial liabilities measured at amortized cost |
Of which fair value by level1 |
|
|---|---|---|---|---|---|---|---|
| December 31, 2019 | 1 | 2 | |||||
| Derivatives | 971 | 325 | 646 | - | - | - | 971 |
| Non-current financial assets Total assets |
96 1,067 |
- 325 |
- 646 |
96 96 |
- 0 |
96 96 |
- 971 |
| Derivatives | 991 | 759 | 232 | - | - | - | 991 |
| Financial liabilities Current financial liabilities |
8,243 | - | - | 8,243 | - | - | |
| Non-current financial liabilities |
42,984 | 13,167 | - | - | 29,817 | - | 13,167 |
| Total liabilities | 52,218 | 13,926 | 232 | - | 38,060 | - | 14,158 |
| December 31, 2018 | |||||||
| Derivatives | 1,255 | 294 | 961 | - | - | - | 1,255 |
| Non-current financial assets | 87 | - | - | 87 | - | 87 | - |
| Total assets | 1,342 | 294 | 961 | 87 | 0 | 87 | 1,255 |
| Derivatives | 443 | 399 | 44 | - | - | - | 443 |
| Financial liabilities | |||||||
| Current financial liabilities Non-current financial |
10,300 | 905 | - | - | 9,395 | - | 905 |
| liabilities | 43,442 | 16,083 | - | - | 27,359 | - | 16,083 |
| Total liabilities | 54,185 | 17,387 | 44 | - | 36,754 | - | 17,431 |
1 No financial instruments have been classified to level 3
The total fair value of the above financial liabilities, excluding lease liabilities, is SEK 49,106m (54,434). The fair value of trade receivables, other current and non-current receivables, cash and cash equivalents, trade payables and other current and noncurrent liabilities is estimated to be equal to their carrying amount.
No transfers between level 1 and 2 were made during the period.
Guidelines for Alternative Performance Measures (APMs) for companies with securities listed on a regulated market in the EU have been issued by the European Securities and Markets Authority (ESMA). These guidelines are to be applied for APMs not supported under IFRS.
This interim report refers to a number of performance measures not defined in IFRS. These performance measures are used to help investors, management and other stakeholders analyze the company's operations. These non-IFRS measures may differ from similarly titled measures among other companies. Essity's 2018 Annual Report (pages 64-69) describes the various non-IFRS performance measures that are used as a complement to the financial information presented in accordance with IFRS. A number of non-IFRS performance measures have been changed since the publication of the Annual Report and these are presented below. Tables are also presented that show how the performance measures have been calculated.
Investments in operating assets through leases: Assets that are directly attributable to operating activities. Primarily leases for distribution centers.
Investments in non-operating assets through leases: Assets that are not directly attributable to operating activities. Primarily leases for offices.

Description: Operating cash flow consists of the sum of operating cash surplus and change in working capital, with deductions for the net of capital expenditures in non-current assets and restructuring costs.
Reason for use: This is an important control measure in operating activities that the units have control over themselves.
Description: Operating cash flow consists of the sum of operating cash surplus and change in working capital, with deductions for the net of capital expenditures in non-current assets and restructuring costs as well as investments in operating assets through leases.
Reason for use: This is an important control measure in operating activities that the units have control over themselves.
| SEKm | 1912 | 1812 |
|---|---|---|
| Total assets | 162,295 | 154,266 |
| -Financial receivables | -6,988 | -5,181 |
| -Non-current non-interest bearing liabilities | -7,169 | -9,037 |
| -Current non-interest bearing liabilities | -34,397 | -30,745 |
| Capital employed | 113,741 | 109,303 |
| SEKm | 2019:4 | 2019:3 | 2019:2 | 2019:1 | 2018:4 |
|---|---|---|---|---|---|
| Personal Care | 44,268 | 45,630 | 45,272 | 45,033 | 41,768 |
| Consumer Tissue | 47,345 | 48,421 | 47,821 | 48,380 | 44,915 |
| Professional Hygiene | 22,996 | 24,332 | 24,245 | 24,403 | 22,153 |
| Other | -868 | -447 | -1,176 | -1,642 | 467 |
| Capital employed | 113,741 | 117,936 | 116,162 | 116,174 | 109,303 |
| SEKm | 1912 | 1812 |
|---|---|---|
| Inventories | 15,764 | 15,234 |
| Accounts receivables | 19,864 | 18,687 |
| Other current receivables | 2,113 | 2,599 |
| Accounts payables | -15,802 | -15,911 |
| Other current liabilities | -14,998 | -12,792 |
| Adjustments | -159 | -249 |
| Working capital | 6,782 | 7,568 |
| SEKm | 1912 | 1812 |
|---|---|---|
| Surplus in funded pension plans | 2,841 | 1,117 |
| Non-current financial assets | 694 | 634 |
| Current financial assets | 525 | 422 |
| Cash and cash equivalents | 2,928 | 3,008 |
| Financial receivables | 6,988 | 5,181 |
| Non-current financial liabilities | 43,079 | 43,500 |
| Provisions for pensions | 5,866 | 5,258 |
| Current financial liabilities | 8,983 | 10,827 |
| Financial liabilities | 57,928 | 59,585 |
| Net debt | 50,940 | 54,404 |

| SEKm | 1912 | 1812 | 2019:4 | 2018:4 |
|---|---|---|---|---|
| Operating profit | 14,349 | 10,759 | 4,538 | 3,216 |
| -Amortization of acquisition-related intangible assets | 778 | 732 | 202 | 195 |
| -Depreciations | 5,815 | 5,443 | 1,499 | 1,416 |
| -Depreciations Right-of-use asset | 884 | 0 | 224 | 0 |
| -Items affecting comparability, depreciations | -27 | 445 | -17 | -96 |
| -Impairment | 79 | 19 | 75 | 9 |
| -Items affecting comparability, impairment of acquisition-related | ||||
| intangible assets | 0 | 69 | 0 | 64 |
| EBITDA | 21,878 | 17,467 | 6,521 | 4,804 |
| -Items affecting comparability excluding depreciation and impairment | 740 | 930 | 19 | 72 |
| Adjusted EBITDA | 22,618 | 18,397 | 6,540 | 4,876 |
| SEKm | 1912 | 1812 | 2019:4 | 2018:4 |
|---|---|---|---|---|
| Operating profit | 14,349 | 10,759 | 4,538 | 3,216 |
| -Amortization of acquisition-related intangible assets | 778 | 732 | 202 | 195 |
| -Operating profit before amortization of acquisition-related intangible | ||||
| assets/EBITA | 15,127 | 11,560 | 4,740 | 3,475 |
| EBITA margin (%) | 11.7 | 9.8 | 14.1 | 11.2 |
| -Items affecting comparability cost of goods sold | 243 | 1,437 | 11 | -71 |
| -Items affecting comparability, sales and administration costs | 470 | -62 | -9 | 47 |
| Adjusted EBITA | 15,840 | 12,935 | 4,742 | 3,451 |
| Adjusted EBITA margin (%) | 12.3 | 10.9 | 14.1 | 11.1 |
| SEKm | 1912 | 1812 | 2019:4 | 2018:4 |
|---|---|---|---|---|
| Personal Care | ||||
| Operating cash surplus | 8,785 | 7,821 | 2,285 | 2,063 |
| Change in working capital | 401 | -410 | 161 | -6 |
| Capital expenditures non-current assets, net | -1,866 | -2,134 | -718 | -814 |
| Restructuring costs, etc. | -644 | -271 | -58 | 1 |
| Operating cash flow before investments in operating assets through leases | 6,676 | 5,006 | 1,670 | 1,244 |
| Investment in operating assets through leases | -181 | 0 | -27 | 0 |
| Operating cash flow | 6,495 | 5,006 | 1,643 | 1,244 |
| Consumer Tissue | ||||
| Operating cash surplus | 8,107 | 5,612 | 2,557 | 1,441 |
| Change in working capital | -553 | 94 | 187 | 920 |
| Capital expenditures non-current assets, net | -2,239 | -3,073 | -734 | -789 |
| Restructuring costs, etc. | -251 | -245 | -103 | -69 |
| Operating cash flow before investments in operating assets through leases | 5,064 | 2,388 | 1,907 | 1,503 |
| Investment in operating assets through leases | -194 | 0 | -50 | 0 |
| Operating cash flow | 4,870 | 2,388 | 1,857 | 1,503 |
| Professional Hygiene | ||||
| Operating cash surplus | 6,589 | 5,630 | 1,966 | 1,553 |
| Change in working capital | 438 | -565 | 261 | -6 |
| Capital expenditures non-current assets, net | -1,402 | -1,337 | -410 | -507 |
| Restructuring costs, etc. | -603 | -365 | -153 | -149 |
| Operating cash flow before investments in operating assets through leases | 5,022 | 3,363 | 1,664 | 891 |
| Investment in operating assets through leases | -84 | 0 | -41 | 0 |
| Operating cash flow | 4,938 | 3,363 | 1,623 | 891 |

| SEKm | 1912 | 2019:4 |
|---|---|---|
| Personal Care | ||
| Organic net sales | 1,549 | 287 |
| Currency effect1 | 1,623 | 523 |
| Acquisition/Disposals | -175 | -89 |
| Reported change | 2,997 | 721 |
| Consumer Tissue | ||
| Organic net sales | 2,754 | 593 |
| Currency effect1 | 1,972 | 582 |
| Acquisition/Disposals | 53 | 0 |
| Reported change | 4,779 | 1,175 |
| Professional Hygiene | ||
| Organic net sales | 1,010 | 222 |
| Currency effect1 | 1,703 | 446 |
| Acquisition/Disposals | 1 | 0 |
| Reported change | 2,714 | 668 |
| Essity | ||
| Organic net sales | 5,297 | 1,111 |
| 1 Currency effect |
5,299 | 1,552 |
| Acquisition/Disposals | -121 | -89 |
| Reported change | 10,475 | 2,574 |
| 1Consists only of currency translation effects |
Essity conducted sales in approximately 150 countries and had approximately 47,000 employees in 2019.
| Personal Care | 37% |
|---|---|
| of which | |
| Incontinence Products | 17% |
| Medical Solutions | 7% |
| Baby Care | 7% |
| Feminine Care | 6% |
| Consumer Tissue | 39% |
| Professional Hygiene | 24% |
| Net sales in 2019 by region | |
|---|---|
| Europe | 55% |
| Asia | 16% |
| North America | 14% |
| Latin America | 13% |
| Other | 2% |
| Retail | 58% |
|---|---|
| Business-to-business | 24% |
| Healthcare sector | 18% |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.